233 related articles for article (PubMed ID: 27721874)
21. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
Sun WY; Choi J; Cha YJ; Koo JS
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
27. An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer.
Nishimura R; Osako T; Okumura Y; Nakano M; Ohtsuka H; Fujisue M; Arima N
Oncol Lett; 2022 Aug; 24(2):245. PubMed ID: 35761943
[TBL] [Abstract][Full Text] [Related]
28. BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database.
Hwang KT; Kim K; Chang JH; Oh S; Kim YA; Lee JY; Jung SH; Choi IS
Cancer Res Treat; 2018 Jul; 50(3):658-669. PubMed ID: 28701032
[TBL] [Abstract][Full Text] [Related]
29. The different prognostic impact of age according to individual molecular subtypes in breast cancer.
Kim NH; Bang HW; Eom YH; Choi SH
Ann Surg Treat Res; 2022 Sep; 103(3):129-144. PubMed ID: 36128031
[TBL] [Abstract][Full Text] [Related]
30. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.
Dawson SJ; Makretsov N; Blows FM; Driver KE; Provenzano E; Le Quesne J; Baglietto L; Severi G; Giles GG; McLean CA; Callagy G; Green AR; Ellis I; Gelmon K; Turashvili G; Leung S; Aparicio S; Huntsman D; Caldas C; Pharoah P
Br J Cancer; 2010 Aug; 103(5):668-75. PubMed ID: 20664598
[TBL] [Abstract][Full Text] [Related]
31. Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes.
Utsumi T; Kobayashi N; Hikichi M; Ushimado K; Kuroda M
Fujita Med J; 2021; 7(4):130-135. PubMed ID: 35111557
[TBL] [Abstract][Full Text] [Related]
32. [Expression of epithelial cell adhesion molecule and molecular subtypes and prognosis of breast cancer].
Li X; Fu L; Liu M; Fu M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Mar; 41(3):258-63. PubMed ID: 27033789
[TBL] [Abstract][Full Text] [Related]
33. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer.
Ayadi EZ; Cherif B; Ben Hamed Y; Mokni M; Rebai A; Ayadi H; Jlidi R
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3557-3564. PubMed ID: 30583683
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of prolactin receptor expression in breast cancer subtypes].
Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF
Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231
[TBL] [Abstract][Full Text] [Related]
36. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype.
Wu X; Baig A; Kasymjanova G; Kafi K; Holcroft C; Mekouar H; Carbonneau A; Bahoric B; Sultanem K; Muanza T
Cureus; 2016 Dec; 8(12):e924. PubMed ID: 28090417
[TBL] [Abstract][Full Text] [Related]
37. Prognostic influences of B-cell lymphoma 2-positive expression on late recurrence in breast cancer.
Kim HJ; Eom YH; Choi SH
Ann Surg Treat Res; 2023 Jul; 105(1):20-30. PubMed ID: 37441325
[TBL] [Abstract][Full Text] [Related]
38. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
[TBL] [Abstract][Full Text] [Related]
39. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival.
Vasconcelos I; Hussainzada A; Berger S; Fietze E; Linke J; Siedentopf F; Schoenegg W
Breast; 2016 Oct; 29():181-5. PubMed ID: 27544822
[TBL] [Abstract][Full Text] [Related]
40. Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer.
Hwang KT; Kim YA; Kim J; Oh HJ; Park JH; Choi IS; Park JH; Oh S; Chu A; Lee JY; Hwang KR
Sci Rep; 2021 Jun; 11(1):11942. PubMed ID: 34099764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
